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SUMMARY 
We reviewed cancer immunotherapy which means the modulating and using of the patient’s own immune 
system to target the cancer cells rather than using an extrinsic means of therapy. Cancer immunotherapies can be 
classified as either passive or active. It can also be further divided into nonspecific and specific types. The use of 
immunostimulants, non-specific approach, for cancer therapy is one of the earliest approaches in immunotherapy 
that aims to enhance the activity of the lymphocytes that are already attacking to the tumour cells but are 
insufficient to produce a full-powered immune response.   In this review, radioimmunotherapy (coupling a 
radioactive atom to a monoclonal antibody (mAb)), immunotoxins (generated by coupling plant-derived or 
bacterial toxins to mAbs), antibody-directed enzyme prodrug therapy (an antibody is used as a vector to transfer 
an enzyme) and immunomodulators were among the discussed approaches to use mAbs as an anti-cancer. A new 
and promising immunotherapy that is especially highly effective against metastatic melanoma, Adoptive cell 
therapy (ACT), and different cancer vaccines were also reviewed in detail. 
Keywords: Adoptive cell therapy, Cancer immunotherapy, Cancer Vaccines, Immunostimulants, Monoclonal 
antibodies 
 
1. INTRODUCTION 
Cancer immunotherapy, also called biological therapy of cancer, means the modulating and using of the patient’s 
own immune system to target the cancer cells rather than using an extrinsic means of therapy. In that manner, 
cancer immunotherapy focuses on developing agents that activates or enhances the immune system’s recognition 
and killing of the cancer cells (Sharma et al., 2011). 
Cancer immunotherapies can be either passive or active (Todar, 2008). Passive therapy is based on the 
adoptive transfer of immunomodulators (including cytokines), tumor-specific antibodies, 
or immune cells (Rescingo et al., 2007). These substances, or cells, are then administered to the patient 
to initiate an antitumor action. In general, these therapies donot generate immunologic memory and, therefore, 
require chronic infusion-based treatment (McNeel et al., 2007). Several passive immunotherapies have been 
approved for use in breast cancer, melanoma, renal cell carcinoma, leukemia, and various other hematologic and 
solid tumors (Dudley et al., 2005).  
Active immunotherapy, on the other hand, stimulates the patient’s immune system, with the intent of 
promoting an antigen-specific antitumor effect using the body’s own immune cells (McNeel et al., 2007). In 
addition, active immunotherapy seeks to create a durable antitumor response that can protect against minimal 
residual disease and tumor recurrence (Marrari et al., 2007). 
Immunotherapy can be further divided into nonspecific and specific types:  Nonspecific immunotherapy 
involves the administration of cells or substances that are not targeted to a specific antigen. Lymphokine 
activated killer (LAK) cell therapy is an example of a nonspecific cellular immunotherapy currently being 
investigated for the treatment of cancers such as melanoma, renal cell carcinoma, and non-Hodgkin’s lymphoma 
(Clark et al., 1990). 
This approach is based on the concept that leukocytes activated ex vivo by interleukin-2 can lyse tumor 
cells that are resistant to natural killer cells. Other types of nonspecific approaches have been approved for renal, 
bladder, and other cancers, and may exert a wide range of effects on the immune system (Emeryville, 2008). 
Conversely, active specific immunotherapy involves the priming of the immune system in order to 
generate a T-cell response against tumor-associated antigens (Kipp and McNeel, 2007). One example of the 
active specific approach is adoptive T-cell therapy, which involves the ex vivo cultivation of T cells with 
demonstrated activity against a specific target cancer antigen  The goal is to increase the frequency of these T 
cells to achieve therapeutic levels and then infuse them back into the patient. This approach is highly specific 
and has been investigated for the treatment of melanoma (Wrszesinski et al., 2007). 
 
2. IMMUNOSTIMULANTS 
The use of immunostimulants for cancer therapy is one of the earliest approaches in immunotherapy. It is a non-
specific approach that aims to enhance, in general, the activity of the lymphocytes that are already attacking to 
the tumour cells but are insufficient to produce a full-powered immune response. In this manner, this strategy 
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uses the patient’s own immune system as the effecting factor. In the late 1980s and early 1990s, the most 
important cytokines for cancer therapy, Interleukin-2 (IL-2) and Alpha-Interferon (IFN-α), demonstrated their 
anti-cancer properties and were approved by the U.S. Food and Drug Administration (FDA) for the treatment of 
diverse types of cancers including metastatic melanoma and renal cell carcinoma (Kirkwood et al., 2008). 
Alpha-Interferons are proteins belonging to the type-I IFN family which was discovered decades ago 
for its anti-viral properties (Belardelli, 1995). The human IFN-α family consist of at least 13 functional subtypes 
which share the same receptor system and very similar biological functions (Mogensen et al, 1999). These 
diverse biological functions include the activation and regulation of both innate and adaptive immune system by 
enhancing the effects of macrophage and natural killer (NK) cells, increasing the expression of Major 
Histocompatability (MHC) class I antigens, and regulating the proliferation and survival of both helper and 
cytotoxic T-cells.   
Alpha- Interferon (IFN-α) has also direct effects on cancer cells by its apoptotic, antiangiogenic and 
antiproliferative properties (Belardelli et al., 2002). In today’s immunotherapy regimes, IFN-α is the most used 
cytokine for the treatment of more than a dozen types of cancer, such as hairy cell leukemia, chronic myeloid 
leukemia, B and T cell lymphomas, melanoma, renal carcinoma and Kaposi’s sarcoma (Pfeffer et al., 1998 ). 
Inteleukin-2 (IL-2) is a glycoprotein which is a strong T-cell and NK- cell growth factor that plays a 
key role in immune regulation and lymphocyte proliferation. Unlike IFN-α, IL-2 has only indirect anti-cancer 
effects through the activation of the effector lymphocytes which are also called lymphokine-activated killer cells 
(Fang et al., 2008). The drawbacks of this immunotherapy are its high cost and its severe but reversible adverse 
effects. Nevertheless, to this date, IL-2 remains to be an indispensible immunotherapeutic agent for the treatment 
of metastatic melanoma (Fang et al., 2008).  
Apart from IL-2 and IFN-α , Bacillus Calmette-Guerin (BCG) , Levamisole and Granulocyte-
macrophage colony-stimulating factor (GM-CSF) have also being used as immunostimulants over the years for 
immunotherapy but mostly in combinations with other immunotherapies or other strategies for anti-cancer 
therapeutics (Waller, 2007). 
 
3. CANCER THERAPY WITH MONOCLONAL ANTIBODIES 
A century ago, an idea was set forth by Paul Ehrlich that suggested the use of antibodies to selectively target 
tumours. Over the years, this concept became applicable with the development of hybridoma technology by 
Kohler and Milstein and further by the generation of chimeric and humanized monoclonal antibodies (mAbs) to 
increase their immunogenicity and their ability to activate and channel the effector immune mechanisms (Adams 
and Weiner, 2005). Today, the monoclonal antibodies play a crucial role in cancer immunotherapy through their 
diverse range of effects and targets. The mechanisms of mAb actions  include direct toxicity which consists of 
antibody-dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC), directing and 
enhancing the activity of effector immune cells, slowing tumour growth and delivering radioactive isotopes, 
toxins or chemotherapeutic drugs to tumour cells (Bisht et al.,2010). 
 
Source: (Bisht et al., 2010) 
Figure 1: Different mechanisms of action of mAbs in cancer immunotherapy. AB, Antibody, CDC, Complement 
Dependent Cytotoxicity, ADCC, antibody-dependent cellular cytotoxicity, VEGF, Vascular Endothelial Growth 
Factor 
Antibody-dependent cellular cytotoxicity (ADCC) and CDC outline one of the common mechanisms of 
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the mAbs. Antibody-dependent cellular cytotoxicity (ADCC) can be considered as a mechanism to directly 
provoke an acute tumour destruction in variable levels which also leads to antigen presentation and the activation 
of adaptive immune components against cancer cells (Adams and Weiner, 2005).  
Complement dependent cytotoxicity (CDC) acts on cell membranes where the complement cascade 
ends up forming a 100 Å pores that result cell death because of the uncontrolled passage of contents into and out 
of the cell (Gelderman et al., 2004).  The applications and efficacy of the mAbs for anti-cancer therapies can be 
further improved by administrating them in combination with other anti-cancer therapies such as chemotherapy, 
radiotherapy, targeted therapy agents and cancer vaccines (Weiner et al, 2010). 
 
3.1. Radioimmunotherapy  
As mentioned above, one of the techniques to extend the use of monoclonal antibodies is to couple a radioactive 
atom to a mAb which is targeting a tumour specific antigen. This approach is called radioimmunotherapy in 
which, the goal is to limit the application of the deadly radiation to those of tumour cells and keep the toxicity at 
minimal for the healthy cells (Dimberu and Leonhardt, 2011).  
There are currently two FDA approved radioimmunotherapy agents that are being used for the 
treatment of B-cell malignancies; the radioactive isotope yttrium-90 with an IgG1 mAb against CD20 antigen on 
B-cells, 90Y-ibritumomab tiuxetan (Zevalin®), and the radioactive isotope iodine-131 with an IgG2a mAb that 
is also against CD20, 131Itositumomab (Bexxar®) (Waldmann , 2003). 
 
3.2. Immunotoxins  
Immunotoxins are generated by coupling plant-derived or bacterial toxins to mAbs that target specific antigens 
on the surface of cancer cells. The first developed toxins for this purpose included gelonin, ricin, abrin, 
pokeweed antiviral protein, Pseudomonas exotoxin and Diphtheria toxin. However, due to several drawbacks of 
these techniques such as rapid clearance from blood stream and immunogenicity led to the generation of the 
second cohort immunotoxins such as BL22 and moxetumomab pasudotox (Teicher and Chari, 2011). Both 
immunotoxins are anti-CD22-Pseudomonas exotoxins that are recently being tested in clinical trials for the 
treatment of B-cell malignancies and other hematological malignancies (Kreitman and Pastan, 2011). 
 
3.3. Antibody-Directed Enzyme Prodrug Therapy  
Another approach to use mAbs as an anti-cancer therapy is called antibody-directed enzyme prodrug therapy 
(ADEPT) where an antibody is used as a vector to transfer an enzyme that is capable of activating an initially 
nontoxic drug, called a "prodrug," to a potently cytotoxic agent for tumour cells (Melton and  Sherwood, 1996).  
In this method, an antibody-enzyme conjugate is injected and allowed to localize at the tumour cells depending 
the specificity of the antibody. Then, the prodrug is administered that should be converted to a cytotoxic agent 
only within the tumour tissue where the activating enzyme resides even though the initial reaction towards the 
ADEPT technology was promising; this approach has not been further developed due to its drawbacks, such as 
immunogenicity of the enzyme components, short half-life of the conjugates and the observed little anti-tumour 
activity from in vivo studies (Teicher and Chari, 2011). 
 
3.4. Immunomodulators 
There are several key regulatory elements, also called ‘immune-checkpoints’, in the immune system that 
manages the level of immune response by the means of down regulation and inhibition to restore the homeostasis. 
These critical elements are absolute necessity for the development of self-tolerance and to prevent autoimmunity, 
however, tumour cells constantly benefit from this property of the immune system in order to escape from its 
destructive power (Dimberu and Leonhardt, 2011). 
There are several approaches to prevent this inhibition of immune response and to enhance the duration 
and activation of the T-cell mediated immunity; increasing the expression of co-stimulatory factors on the 
surface of dendritic cells (DC) by the CD-40 or toll-like receptor 9 (TLR-9) stimulation of DCs (Krieg , 2006), 
and enhancing and prolonging the T-cell activation by inhibiting the cytotoxic T-lymphocyte antigen-4 (CTLA-4) 
or programmed death-1 (PD-1) binding to B7 or to PD1 ligand (PDL-1) respectively (Ribas  et al., 2005). 
Cytotoxic T-lymphocyte antigen-4 (CTLA-4), a homolog of CD-28 that functions as an inhibitory 
receptor for B7 co-stimulatory molecules on mature antigen presenting cells (APC), is the main negative 
regulatory element of the T-cell mediated anti-tumour immune response since its binding to B7 down regulates 
the T-cell activation (Kirkwood et al., 2008). Two anti-CTLA-4 mAbs that are in clinical trials now, Ipilimumab 
and Tremelimumab, therefore were developed to block the CTLA-4 binding to B7 through their higher affinities 
for the CTLA-4 than the B7 and so, competitively inhibiting the down regulation of T-cells (Ribas et al., 2005). 
Ipilimumab binds and blocks CTLA-4 and has recently shown striking clinical successes against metastatic 
melanoma that has led to its FDA approval in 2011 (Dimberu and Leonhardt 2011). 
Journal of Health, Medicine and Nursing                                                                                                                                          www.iiste.org 
ISSN 2422-8419     An International Peer-reviewed Journal 
Vol.25, 2016 
 
18 
 
 
 
Source:  (Kirkwood et al., 2008) 
Figure 2: The CTLA-4 blockade by an Anti-CTLA-4 mAb prevents T-cell down regulation. (A) Activation of T-
cells initiates the upregulation and binding of CTLA-4 receptors to B7 receptors on the dendritic cells sending 
inhibitory signals to down regulate the T-cell activation. (B) Anti-CTLA-4 mAb binds to CTLA-4 receptor and 
blocks the B7 binding therefore prolonging the T-cell activation. 
Apart from the CTLA-4 and PD-1 blockade, another recently developed approach to avoid the 
suppression and to enhance the activation of immune response is the increase of the expression of co-stimulatory 
factors on the surface of DCs by a TLR-9 agonist.  Toll like receptor-9(TLR-9) is an intracellular receptor that 
recognizes un-methylated cytosine-guanine (CpG) dinucleotides which are frequently found in viral and 
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bacterial DNAs (Krieg, 2002). Stimulation by TLR-9 agonist induces the activation/maturation of the DCs by 
resulting in an increase in surface expression of co-stimulatory molecules, secretion of cytokines/ chemokines, 
activation of NK-cells, and antigen presentation (West et al., 2004; Pashenkov et al., 2006). 
 
Source: (Kirkwood et al., 2008). 
Figure 3: Toll-like receptor-9 (TLR-9) agonists induce the activation and maturation of dendritic cells which 
increases the expression of co-stimulatory molecules on the surface that also causes the production of the 
adaptive immune response.   
 
4. ADOPTIVE CELL THERAPY  
Adoptive cell therapy (ACT) is a new and promising immunotherapy that is especially highly effective against 
metastatic melanoma (Rosenberg and Dudley, 2009). In ACT, the T cells of a patient that have anti-tumour 
activity are identified, isolated, grown ex vivo, further stimulated by the tumour-APCs and infused back to the 
same patient  (Dimberu and Leonhardt, 2011). 
Before this infusion of the high amounts of tumour-infiltrating lymphocytes (TILs), the host can be 
manipulated in order to increase the effectiveness of the transferred cells. Patients normally undergo a 
lymphodepletion with either chemotherapy or body irradiation before the infusion that not only provides the 
elimination of the regulatory T cells which have immunosuppressive activities, but also eliminates the other 
lymphocytes that can compete with the transferred cells for cytokines that are essential for T-cell survival such 
as interleukin 7 (IL-7) and interleukin 15 (IL-15) (Rosenberg and Dudley, 2009). For the same purpose, vaccines 
or growth factors, such as IL-2, can also be infused along with the transferred cells (Rosenberg et al., 2008). 
 
Figure 4: A schematic explaining the basic principles of ACT as discussed above. (From Research projects - 
Villadangos Laboratory – The University of Melbourne – Department of Microbiology and immunology, 2011. 
Understanding the mechanisms that impair anti-tumour Adoptive Cell Therapy. [Online] (Updated on 25 
October 2011 15:14:24) Available 
at<http://www.microbiol.unimelb.edu.au/research/immunology/villadangos/villadangos_research_proj_p2.html#
vp6 > [Accessed on 18 August 2015]). 
 
5. CANCER VACCINES 
Cancer vaccines probably create one of the most diverse classes in the immunotherapeutic approaches where it is 
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also the case for the use of monoclonal antibodies. The development of cancer vaccines can be divided into two 
groups; preventative, also called prophylactic, and therapeutic. These groups are also further sub-grouped and 
some examples of each are briefly discussed here (Table 1).  
Table 1: The classification of diverse cancer vaccines in immunotherapy 
Vaccine type Name of the Agent Against to  
Preventative 
  
Virus-based  Hepatitis B virus vaccine Hepatocellular Carcinoma  
 
Human Papilloma virus vaccines: 
Gardasil and Cervarix 
Cervical Cancer 
Therapeutic  
  
Peptide or Protein-based  Vitespen 
Melanoma and locally renal cell 
carcinoma advance 
 
Gp100  Melanoma  
Autologous or Allogeneic 
Whole-Tumour-Cell  
GVAX  Prostate Cancer  
Dendritic-Cell-based  Sipuleucel-T (Provenge)  Advance metastatic prostate cancer  
 
DCVAX-Prostate  Prostate Cancer 
 
DCVAX-Brain  Glioblastoma 
Gene Therapy-based  ProstVac-VF  Prostate Cancer  
Idiotype-Immunoglobulin-based  BiovaxID  Non-Hodgkin’s lymphoma  
Preventative cancer vaccines are being used with relative success for more than 30 years to prevent the 
increased chance of tumorigenesis caused by various viral infections. Currently, there are six human viruses 
identified which are indicated as carcinogenic to humans: hepatitis B virus (HBV), human papilloma virus 
(HPV), Epstein–Barr virus (EBV), human immunodeficiency virus type-1 (HIV-1), hepatitis C virus (HCV) and 
Kaposi’s sarcoma-associated herpes virus (KSHV) (Sarid and  Gao ,2011). However, there are currently no 
vaccines against these viruses with the exception of first two viruses. The very first such preventative cancer 
vaccine was the HBV vaccine in which, it was approved by FDA in 1981 and since then it has been used as one 
of the standard agents in scheduled routine vaccinations for infants (Dimberu and Leonhardt, 2011). The 
common use of this HBV vaccine not only dramatically reduced the rates of HBV infections but also reduced the 
number of incidences of Hepatocellular Carcinoma (HCC) where the immunization provided by this vaccine 
continued well for vaccinated individuals even in later ages (Chang et al., 2009). 
The second preventative cancer vaccine is the human papilloma virus vaccine. In the 1980s, it was 
demonstrated (by Harald zur Hausen) that certain HPV types, HPV16 and HPV18, were present in most cervical 
cancer biopsies and also in cervical cancer-derived cell lines (Hausen, 2009). Nowadays, HPV is known to be 
responsible for virtually all cases of cervical cancer in which the HPV16 and HPV18 are the high-risk HPVs that 
consist the almost 80% of the cervical cancer incidences (Sarid and Gao, 2011). 
Apart from preventative vaccines, the therapeutic cancer vaccines aim to raise an immune response to 
an existing cancer rather than trying to prevent it from forming. This approach has been developed due to 
realization that the cancer patients can indeed produce both cytotoxic and helper T cells specific to antigens 
expressed in their tumours (Boon et al., 2006). Therapeutic cancer vaccines intent to trigger or enhance these 
pre-existing T cell responses against the tumour cells and there are several different approaches in the making of 
these vaccines (Mellman et al., 2011). 
 
5.1. Peptide or Protein-Based Vaccines 
This type of cancer vaccines use a whole protein or short peptide derived from the tumour cells as a tumour cell-
specific antigen for the immunization. A vaccine belongs to this type, called Vitespen, is a peptide-based vaccine 
which uses an autologous tumour-derived heat shock (chaperone) protein; glycoprotein (gp) 96–peptide complex 
(HSPPC-96) as an antigen (Hammerstrom et al., 2011). In phase III clinical studies against Melanoma and 
locally advance renal cell carcinoma, Vitespen has failed to provide a significant increase in overall survival 
rates and showed no overall benefit in recurrence-free survival (Wood et al., 2008 and Testori et al., 2008). 
However, these studies showed an insignificant benefit with patient in earlier stages and also the subgroup 
analysis indicated that patients with higher doses of Vitespen survived longer than ones with the lower doses 
(Hammerstrom et al., 2011). 
Another peptide-based therapeutic cancer vaccine is called Gp100 (or Gp100-based) that uses peptides 
from this glycoprotein 100 as a melanoma associated antigen for the vaccination. Eventhough this vaccine has 
succeeded to demonstrate its ability to establish an immune response against the tumour cells, no reduction in 
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tumour size was observed (Hodi et al., 2010). However a recent study, where Gp100 was co-administrated with 
the Immunostimulant IL-2, showed an anti-cancer immune response with a prolonged progression-free survival 
rate in patients with advanced melanoma (Schwartzentruber et al., 2011).  
Eventhough there is some potential in the future of peptide or protein-based cancer vaccines, these 
primary studies clearly indicate the difficulties associated with the use of them. These difficulties may arose 
from the fact that short and free peptides are likely to be discarded rather quickly from the body without having 
the chance to associate with a dendritic cell to cause an immune response. Following up from the same problem, 
another issue can be the lack of effective dendritic-cell-activating adjuvant that is supposed to assist the peptides 
to be loaded to dendritic cells and promote their activation and maturation. Circumventing these issues can 
indeed improve the therapeutic benefits provided by these cancer vaccines (Rosenberg et al., 2004). 
 
5.2. Autologous or Allogeneic Whole-Tumour-Cell Vaccines  
Whole-tumour-cell cancer vaccines are prepared from either autologous tumour cells or allogeneic tumour cell 
lines. Eventhough the use of autologous tumour cells eliminates the antigen selection problem by providing the 
advantage of targeting the individual’s own tumour associated antigens, this approached has been abandoned due 
to the motion that this kind of vaccine would not raise an effective anti-cancer immune response since it was not 
pre-existing in the first place (Hammerstrom  et al, 2011). Furthermore, the high complexity of the vaccine 
preparation for each individual patient additionally instigated the abandoning of this approach (Mellman et al., 
2011). In the other hand, the use of allogeneic tumour cell lines for the whole-tumour-cell vaccination was 
favoured because of its ability to introduce multiple antigens and therefore to stimulate a better immune response. 
An example to this class of cancer vaccines is called GVAX which uses Allogeneic Prostate Cancer Cell Lines 
VITAL- 1 and VITAL-2 that are manipulated to secrete GM-CSF (Higano et al., 2008). Despite its success in 
phase I and II clinical trials, the application of GVAX was terminated in phase III clinical trials against prostate 
cancer due to the increased rate of deaths and the low chance of reaching to its end point (Drake, 2009). 
 
5.3. Gene Therapy-Based Vaccines  
Gene therapy-based vaccines are also called vector or viral-vector vaccines since they use viruses to insert the 
vaccine. In this approach, these viral vectors are engineered to encode for specific tumour antigens for the 
purpose of stimulating and enhancing the immune responses against cancer cells that carry the particular 
antigens. While advantages of using viruses as a delivery vehicle includes the easy gene insertion, low cost and 
ability to induce persistent immune response, the viruses belonging to the poxvirus family create an attractive 
candidate for this treatment due to their safe applications since the 1960s (Madan et al., 2009). The recombinant 
poxvirus vaccine, belonging to this class of cancer vaccines, is called ProstVac-VF that encodes for a prostate-
specific antigen (PSA) and the adhesion molecules B7-1, Intercellular Adhesion Molecule-1(ICAM-1) and 
Lethal Factor Antigen-3 ( LFA-3) to boost the T- cell activation by resembling a specialized dendritic cell 
(Mellman  et al., 2011).  
Additionally GM-CSF is administrated along with the vector to further stimulate the immune response. 
In a phase II clinical trial against minimally symptomatic metastatic castration-resistant prostate cancer 
(mCRPC), ProstVac-VF failed to improve progression-free survival but succeeded to demonstrate a significant 
increase in overall survival rates and more than 40% of decrease in death rates, leading to its schedule to be used 
in a large phase III clinical trial (Kantoff et al .,2010 ). 
 
5.4. Idiotype Immunoglobulin-Based Vaccines  
This type of cancer vaccines are prepared by fusing patient’s malignant B lymphoma cells with a myeloma cell 
line in which the resulting heterohybridoma expresses antibodies that consist of patient’s tumour-specific 
antigens called idiotypes (Hammerstrom et al., 2011). Then the idiotypes are isolated from the produced 
antibodies from these heterohybridoma B cells, purified and are coupled to keyhole limpet hemocyanin (KLH) to 
enhance their immunogenic properties by providing specific T-cell responses (Reinis, 2008). The vaccine called 
BiovaxID was developed in such way as a cancer vaccine against the B-cell lymphomas. Three phase III clinical 
trials were performed with this vaccine in which one of them was for patients with follicular non-Hodgkin’s 
lymphoma that the BiovaxID showed increased progression-free survival rates when administrated with GM-
CSF (Schuster et al., 2009). Unfortunately in the other two phase III clinical studies, BiovaxID failed to provide 
a significant clinical benefit which may be due to the differences between the populations of patients or due to 
the time and labour intensive manufacturing method of the BiovaxID (Mellman et al., 2011). 
 
5.5. Dendritic-Cell-Based Vaccines  
Among all the cancer vaccines discussed here, perhaps dendritic-dell-based vaccines hold of the highest 
potentials in the field of therapeutic vaccination that still needs to be explored. Considering the amount of 
information accumulated in the recent decades, the importance of dendritic cells is now known for a potent T-
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cell stimulation and therefore a persistent anti-cancer immune response (Mellman et al., 2011). One of the 
dendritic-dell-based vaccines is called DCVAX-Prostate which is an autologous dendritic cell vaccine however it 
does not use a whole protein as in peptide or protein-based vaccines and it does not include GM-CSF in its 
administration. 
Its manufacturing follows an incubation of the patient’s dendritic cells with a prostate-specific 
membrane antigen (PSMA) before it is infused back in to the same patient (Hammerstrom et al., 2011). The 
phase I and II clinical trials in patients with prostate cancer, DCVAX-prostate proved to be able to induce an 
anti-cancer immune response against the prostate cancer cells (Fishman, 2009). Another dendritic-dell-based 
vaccine is called DCVAX-Brain which uses the exact same concept as in DCVAX-prostate but instead of PSMA 
the autologous dendritic cells are loaded with the patient’s tumour cell lysates. The DCVAX-Brain vaccine is 
used in patients with glioblastoma multiforme which the most aggressive, malignant and common brain tumour 
in humans (Van Meir et al., 2010). As in the case of DCVAX-Prostate, the phase I and II clinical trials of the 
DCVAX-Brain vaccine also showed low toxicity and successful stimulation of an anti-tumour immune response 
(Wheeler and Black, 2009).  
 
5.6. Sipuleucel-T (Provenge)  
The use of Sipuleucel-T for advance metastatic prostate cancer was approved by FDA in 2010; making 
Sipuleucel-T the first FDA approved therapeutic cancer vaccine (Hammerstrom et al., 2011). It is an autologous 
personalized vaccine that is prepared from the patient’s own peripheral blood mononuclear cells. After 
discarding platelets, monocytes, low-density lymphocytes and erythrocytes by leukapheresis, the remaining 
dendritic cells, T cells, B cells, and natural killer cells are incubated from 36 to 44 hour ex vivo with a fusion 
protein PA2024 which is composed of a prostate cancer antigen, prostatic acid phosphates (PAP) and GM-CSF 
( Dimberu and Leonhardt, 2011). After the ex vivo incubation, the cells are infused back into the same patient 
where the cells are thought to effectively present the antigen to host immune system and activate the cytotoxic T-
cell responses against the tumour cells (Drake,2010).  
Eventhough the Sipuleucel-T vaccine is considered as an autologous dendritic-cell-based vaccine, its 
mechanism of action is not fully comprehended since it has not been clearly demonstrated yet whether the 
complex mixture of the ex vivo incubated cells indeed contain the PAP-loaded dendritic cells or that the 
induction of PAP-specific T-cells by the infusion indeed exists (Pardoll and  Drake, 2012). Therefore there is 
still a need for further characterization of the incubated cells to fully understand the mechanism of this vaccine. 
Although the phase III clinical studies of Sipuleucel-T did not show reduction in tumour size or reduction in 
disease progression rate, it succeeded to provide a significant increase in the median survival rates that led to its 
FDA approval. This appearance of increase in overall survival provided by the Sipuleucel-T vaccine without 
demonstration of an observable anti-tumour effect has led to the discussion that the tumour response criteria in 
clinical trials might be in need of modification for this kind of immunotherapeutic approaches (Kantoff et al., 
2010). 
 
Source: (Marie et al., 2012). 
Figure 5: The preparation and proposed mechanism of action of Sipuleucel-T cancer vaccine. PAP: Prostatic 
acid phosphates’, GM-CSF: Granulocyte-macrophage colony-stimulating factor, APC: Antigen presenting cell.  
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6. CONCLUSION 
Cancer immunotherapy focuses on developing agents that activates or enhances the immune system’s 
recognition and killing of the cancer cells. It can be either passive or active.  Passive therapy is based on the 
adoptive transfer of immunomodulators (including cytokines), tumor-specific antibodies, or immune cells while 
active immunotherapy, on the other hand, stimulates the patient’s immune system, with the intent of promoting 
an antigen-specific antitumor effect using the body’s own immune cells. Immunotherapy can be further divided 
into nonspecific and specific types: Nonspecific immunotherapy involves the administration of cells or 
substances that are not targeted to a specific antigen. In contrary to this, active specific immunotherapy involves 
the priming of the immune system in order to generate a T-cell response against tumor-associated antigens. 
Radioimmunotherapy (coupling a radioactive atom to a monoclonal antibody (mAb)), immunotoxins 
(generated by coupling plant-derived or bacterial toxins to mAbs), antibody-directed enzyme prodrug therapy 
(an antibody is used as a vector to transfer an enzyme) and immunomodulators were among the discussed 
approaches to use mAbs as an anti-cancer. 
Peptide or protein-based vaccines (use a whole protein or short peptide derived from the tumour cells), 
autologous or allogeneic whole-tumour-cell vaccines (prepared from either autologous tumour cells or allogeneic 
tumour cell lines), gene therapy-based vaccines(use viruses to insert the vaccine), idiotype immunoglobulin-
based vaccines (prepared by fusing patient’s malignant B lymphoma cells with a myeloma cell line ), dendritic-
cell-based  vaccines and sipuleucel-T (provenge)(prepared from the patient’s own peripheral blood mononuclear 
cells) were among the  cancer vaccines in the immunotherapeutic approaches. 
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